Micafungin Pharmore (Micafungin)

Micafungin works by inhibiting the fungal enzyme β‑(1,3)‑D‑glucan synthase, which is essential for producing β‑(1,3)‑D‑glucan, a critical component of the fungal cell wall. Disruption of cell‑wall synthesis leads to osmotic instability, cell lysis, and ultimately eradication of the fungus.

The dosing regimen for Micafungin Pharmore is determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals set the appropriate dose and infusion rate for each individual case.

The safety of Micafungin during pregnancy and lactation has not been definitively established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Micafungin Pharmore product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Micafungin belongs to the echinocandin class, which differs from azole antifungals by targeting the fungal cell wall rather than ergosterol synthesis. Echinocandins, including Micafungin, generally have a favorable safety profile and are effective against many azole‑resistant Candida species, making them a valuable alternative when azoles are unsuitable.

Micafungin Pharmore should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until preparation for infusion to maintain stability and potency.

Micafungin is given by intravenous infusion. The reconstituted solution is administered over a prescribed period, typically ranging from 30 to 60 minutes, depending on the clinical protocol and patient tolerance. Infusion should be performed by qualified healthcare personnel in a controlled setting.

Serious adverse events include hypersensitivity reactions such as anaphylaxis, significant liver enzyme elevations indicating hepatotoxicity, acute renal impairment, and severe neutropenia. Patients should be monitored closely for signs of allergic response, liver dysfunction, or sudden changes in kidney function during therapy.

Micafungin is contraindicated in patients with known hypersensitivity to Micafungin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, uncontrolled renal failure, or those receiving interacting medications that could lead to toxic drug levels.